TY - JOUR
T1 - Pharmacogenetics in heart failure
T2 - promises and challenges
AU - de Boer, Rudolf A.
AU - van der Harst, Pim
AU - van Veldhuisen, Dirk J.
AU - van den Berg, Maarten P.
PY - 2009/8
Y1 - 2009/8
N2 - Pharmacotherapy remains the cornerstone in the treatment of heart failure. There is a wide variability in the individual's response to treatment, which is at least partially ascribed to genetic factors. Pharmacogenetics studies the differential clinical effects due to genetic variances. Some effects of the major neurohormonal inhibitors like angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers are importantly modulated by genetic polymorphisms. So far, however, this does not result in standard genetic testing before starting specific therapy. This review discusses several important pharmacogenetic targets. Furthermore, it is argued that new and sophisticated high-throughput genetic screens could be employed to develop pharmacogenetic screening further. Prospective large-scale pharmacogenetic studies are warranted as we believe that they will identify new targets for therapy and specific populations that benefit from specific treatments.
AB - Pharmacotherapy remains the cornerstone in the treatment of heart failure. There is a wide variability in the individual's response to treatment, which is at least partially ascribed to genetic factors. Pharmacogenetics studies the differential clinical effects due to genetic variances. Some effects of the major neurohormonal inhibitors like angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers are importantly modulated by genetic polymorphisms. So far, however, this does not result in standard genetic testing before starting specific therapy. This review discusses several important pharmacogenetic targets. Furthermore, it is argued that new and sophisticated high-throughput genetic screens could be employed to develop pharmacogenetic screening further. Prospective large-scale pharmacogenetic studies are warranted as we believe that they will identify new targets for therapy and specific populations that benefit from specific treatments.
KW - beta adrenergic receptor
KW - beta blocker
KW - genetics
KW - heart failure
KW - pharmacogenetics
KW - renin angiotensin system
KW - sympathetic nervous system
KW - ADRENERGIC-RECEPTOR POLYMORPHISMS
KW - ENZYME DELETION POLYMORPHISM
KW - BETA-BLOCKER THERAPY
KW - VENTRICULAR EJECTION FRACTION
KW - BETA(1)-ADRENERGIC RECEPTOR
KW - DILATED CARDIOMYOPATHY
KW - MUSCULAR-DYSTROPHY
KW - MERIT-HF
KW - ALPHA(2C)-ADRENERGIC RECEPTORS
KW - SYNERGISTIC POLYMORPHISMS
U2 - 10.1517/14656560903025171
DO - 10.1517/14656560903025171
M3 - Review article
SN - 1465-6566
VL - 10
SP - 1713
EP - 1725
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 11
ER -